NCT03020797 is a NA clinical trial of Perampanel in Amyotrophic Lateral Sclerosis, sponsored by Stony Brook University.

Who is sponsoring NCT03020797?

NCT03020797 is sponsored by Stony Brook University.

What drugs are being tested in NCT03020797?

Interventions in NCT03020797: Perampanel, Placebo Oral Tablet.

What condition does NCT03020797 study?

NCT03020797 studies Amyotrophic Lateral Sclerosis.

Is NCT03020797 still recruiting?

NCT03020797 is currently terminated. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT03020797

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Terminated NA Last updated 6 May 2023

What this trial tests

NA trial testing Perampanel in Amyotrophic Lateral Sclerosis in 12 participants. Terminated before completion.

Timeline

12 January 2017

Primary endpoint
31 January 2023

8 February 2023

Quick facts

Lead sponsor	Stony Brook University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	12
Start date	12 January 2017
Primary completion	31 January 2023
Estimated completion	8 February 2023
Sites	1 location across United States

Drugs / interventions tested

Perampanel (PERAMPANEL) — full drug profile →
Placebo Oral Tablet — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Stony Brook University

Who can join

Adults 18 to 80, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA for treatment of seizures in patients with epilepsy. In this study, perampanel will be used off-label for adults with ALS at an oral medication dose on the low end of the recommended dose range for epilepsy. This study will consist of two treatments arms: perampanel and matching placebo randomized at a 1:1 ratio. Subjects will receive medication for 9 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Improving clinical trial outcomes in amyotrophic lateral sclerosis.
Kiernan MC, Vucic S, Talbot K, McDermott CJ, et al · · 2021 · cited 205× · PMID 33340024 · DOI 10.1038/s41582-020-00434-z
Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS.
Lanznaster D, de Assis DR, Corcia P, Pradat PF, et al · · 2018 · cited 38× · PMID 30619076 · DOI 10.3389/fneur.2018.01126

Verify or expand the search:

Other trials of Perampanel

Trials testing the same drug.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT04309721 — Perampanel in Focal Status Epilepticus · Phase 3 · terminated
NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Stony Brook University trials

Trials by the same sponsor.

NCT07478250 — First Responder Safety Training (FiRST) · NA · not yet recruiting
NCT07076342 — The Role of mGluR5 in CBT-I · Phase 4 · recruiting
NCT07009691 — Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS · NA · recruiting
NCT07114900 — Randomized Controlled Physical Activity App Intervention for Black Women · Phase 3 · active not recruiting
NCT05245227 — Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03020797 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stony Brook University
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03020797.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing